Providence Cancer Institute of Oregon | Strategic Alliance Partners

Rom S. Leidner, MD, discusses the rationale for studying DPV-001 plus PD-1 inhibition in advanced or metastatic head and neck squamous cell carcinoma.

Rom S. Leidner, MD, discusses data for DPV-001 combined with PD-1inhibition with or without a GITR agonist in advanced or metastatic HNSCC.

Rom S. Leidner, MD, discusses the investigation of T-cell receptor–engineered T-cell immunotherapy for select patients with solid tumors.

Bernard A. Fox, PhD, discusses an off-the-shelf multivalent vaccine that contains cancer’s dark matter combined with anti–PD-1 and anti-GITR antibodies in head and neck cancer.

Alison K. Conlin, MD, discusses patient characteristics that drive second-line treatment decisions for patients with HR-positive, HER2-negative metastatic breast cancer; remaining needs for patients with HR-positive, HER2-negative disease; and the evolving role of oral selective estrogen receptor degraders in patients with ESR1-mutated disease.

Alison K. Conlin, MD, discusses unanswered questions regarding the use of CDK4/6 inhibitors after prior progression on CDK4/6 inhibitors and quality of life considerations in patients with breast cancer.

Alison K. Conlin, MD, discusses the benefits of trastuzumab deruxtecan in HER2-low breast cancer.

Chemotherapy prior to transanal excision surgery demonstrated favorable responses that led to increased organ preservation rates among patients with early rectal cancer, according to findings from the phase 2 NEO trial.